SNDX Stock Summary and Trading Ideas (Syndax Pharmaceuticals | NASDAQ:SNDX)

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

Syndax Pharmaceuticals trades on the NASDAQ stock market under the symbol SNDX.

As of May 15, 2024, SNDX stock price climbed to $21.94 with 594,540 million shares trading.

SNDX has a beta of 2.08, meaning it tends to be more sensitive to market movements. SNDX has a correlation of 0.29 to the broad based SPY ETF.

SNDX has a market cap of $1.86 billion. This is considered a Small Cap stock.

In the last 3 years, SNDX stock traded as high as $29.86 and as low as $11.22.

The top ETF exchange traded funds that SNDX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IBB.

SNDX has underperformed the market in the last year with a price return of +4.1% while the SPY ETF gained +30.3%. SNDX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -0.2% and +3.8%, respectively, while the SPY returned +6.6% and +5.5%, respectively.

SNDX support price is $21.06 and resistance is $22.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNDX stock will trade within this expected range on the day.